Dima Biotechnology
Recombinant monoclonal antibodies and membrane proteins for drug discovery.
Recombinant monoclonal antibodies and membrane proteins for drug discovery.
Dima Biotechnology, established in 2019, is a US-based biotech company focusing on preclinical R&D solutions for the Biopharma industry. The company specializes in the development of recombinant monoclonal antibodies and membrane proteins for drug discovery. Its \n
slogan: Recombinant monoclonal antibodies and membrane proteins for drug discovery.
The company's innovative offerings include the DiMPro™ Membrane Protein Platform, DimAb® Single B Cell Antibody Discovery Platform, DiLibrary™ Mammalian Display Antibody Engineering Platform, and DiAssay™ Antibody Evaluation Platform. Its last investment, an Angel Round, was in September 2019, with funding from Emerging Technology Partners, Guoqian Venture Capital, and Huatai Zijin Investment. Dima Biotechnology aims to accelerate drug discovery for the Biopharma sector, fostering innovation and expediting life-changing therapy development.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Angel Round | Unknown | 3 |
|
11 Sep 2019 |
No recent news or press coverage available for Dima Biotechnology.
We care about your data, and we'd love to use cookies make your experience better.
